Search

Search Constraints

You searched for: Author/Creator Stephen Hodi, F

Search Results

1. 312 Female sex independently predicts adjuvant immunotherapeutic benefit from CTLA4 immune checkpoint inhibition. (9th November 2020)

2. 648 Cytokine changes during immune-related adverse events and steroid treatment in melanoma patients receiving immune checkpoint inhibitors. (9th November 2020)

3. 808 Exploring resistance mechanism to pembrolizumab and ang-2 inhibitor trebananib (NCT03239145) using high-dimensional single-cell mass cytometry (CyTOF). (10th December 2020)

4. C reactive protein impairs adaptive immunity in immune cells of patients with melanoma. Issue 1 (16th April 2020)

5. Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. Issue 1 (19th January 2021)

6. Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. Issue 1 (19th January 2021)

7. Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. Issue 1 (19th January 2021)

8. First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1). Issue 3 (16th March 2023)

9. Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary. Issue 1 (24th January 2022)

10. Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. Issue 1 (16th April 2020)